Loading…
Atossa Therapeutics, Inc. is projected to rise to $2.75 by 2027, a +27% move from its current price of $2.17. ATOS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $2.09 | $2.17 | $2.25 | -0.01% |
| Aug 6 | $2.05 | $2.17 | $2.29 | -0.02% |
| Aug 7 | $2.03 | $2.17 | $2.32 | -0.03% |
| Aug 8 | $2.01 | $2.17 | $2.34 | -0.04% |
| Aug 9 | $1.99 | $2.17 | $2.36 | -0.05% |
| Aug 10 | $1.97 | $2.17 | $2.38 | -0.06% |
| Aug 11 | $1.96 | $2.17 | $2.40 | -0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.96 | $2.17 | $2.40 | -0.07% |
| Week 2 | $1.88 | $2.17 | $2.50 | -0.15% |
| Week 3 | $1.81 | $2.17 | $2.58 | -0.22% |
| Week 4 | $1.76 | $2.16 | $2.65 | -0.29% |
| Week 5 | $1.72 | $2.16 | $2.72 | -0.37% |
| Week 6 | $1.68 | $2.16 | $2.77 | -0.44% |
| Week 7 | $1.65 | $2.16 | $2.83 | -0.51% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines in areas of significant unmet medical need in oncology in the United States.
Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
ATOS is currently priced at $2.07 per share and has a market capitalization of $20.65M, ranking 4854.
The current price sits within a broader forecast that shows a bullish trajectory beginning in the later years, with 2026 offering an avg of $2.07 and 0% ROI, and subsequent years showing higher avg targets and positive ROIs.
Looking further out, the forecast projects an increasing avg price reaching $7.57 by 2050 with a max of $16.12 and a long-run bullish sentiment, indicating meaningful upside relative to today’s level.
A major floor 37.2% below — a decisive break under it would weaken the trend.
The nearest floor, 19.4% below — buyers have tended to step in here.
The nearest ceiling, 14.7% above — a clean break opens room to run.
A major ceiling 184.3% above — clearing it would confirm fresh momentum.
Key ATOS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ATOS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.27 | Sell | $2.23 | Sell |
| MA 10 | $2.34 | Sell | $2.29 | Sell |
| MA 20 | $2.37 | Sell | $2.37 | Sell |
| MA 50 | $3.01 | Sell | $2.99 | Sell |
| MA 100 | $4.16 | Sell | $4.16 | Sell |
| MA 200 | $6.95 | Sell | $6.28 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.15 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -248.11 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | -15.16 | Sell |
| Bollinger %B (20,2) | -0.21 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.04 | Sell |
| Awesome (5,34) | 0.05 | Buy |
| Ultimate (7,14,28) | 29.60 | Buy |
| Momentum (10) | -0.42 | Sell |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 2.19 | Sell |
| ADX (14) | 25.71 | Sell |
| ATR (14) | 0.10 | Info |
The 30-day technical picture is NEUTRAL.
RSI14 is 30, with a SMA50 of $3.01 and a SMA200 of $6.95. Near-term support sits at $1.75 and resistance at $2.49. The 30-day price range runs from $1.61 to $2.67, and the stock exhibits an annualized volatility of 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.75 | $2.17 | $3.13 | 0% | Neutral | |
| $2.11 | $2.75 | $3.82 | +27% | Bullish | |
| $2.33 | $3.17 | $4.64 | +46% | Bullish | |
| $2.10 | $2.95 | $4.50 | +36% | Bullish | |
| $1.90 | $2.75 | $4.33 | +27% | Bullish | |
| $1.97 | $2.94 | $4.76 | +36% | Bullish | |
| $1.80 | $2.76 | $4.57 | +27% | Bullish | |
| $1.98 | $3.12 | $5.28 | +44% | Bullish | |
| $2.40 | $3.87 | $6.69 | +78% | Bullish | |
| $2.45 | $4.03 | $7.10 | +86% | Bullish | |
| $2.56 | $4.71 | $8.98 | +117% | Bullish | |
| $3.57 | $7.93 | $16.90 | +266% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.75 | $2.17 | $2.72 | +0.00% |
| September 2026 | $1.83 | $2.18 | $2.70 | +0.65% |
| October 2026 | $1.78 | $2.15 | $2.70 | -1.59% |
| November 2026 | $1.89 | $2.31 | $2.93 | +7.28% |
| December 2026 | $1.99 | $2.44 | $3.13 | +5.74% |
Click any year to see its month-by-month ATOS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ATOS is projected to trade between $1.75 and $3.13, averaging $2.17 — a potential gain of 0% from today's $2.17. Price action looks broadly range-bound.
Atossa Therapeutics, Inc.'s 2027 outlook centres on $2.75, within a $2.11 to $3.82 range. That is up +27% on the projected 2026 average. That marks a +27% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, ATOS could reach as high as $4.64, with a base case around $3.17 and support toward $2.33 — roughly +46% from $2.17. Momentum favours further upside here.
Expect ATOS to range from $2.10 to $4.50 through 2029. The $2.95 average target implies a +36% move from current prices. That is -7% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
The ATOS price prediction for 2030 points to an average of $2.75 (low $1.90, high $4.33) — a potential gain of +27% on today's $2.17. Momentum favours further upside here.
In 2031, ATOS is projected to trade between $1.97 and $4.76, averaging $2.94 — a potential gain of +36% from today's $2.17. That is up +7% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Atossa Therapeutics, Inc.'s 2032 outlook centres on $2.76, within a $1.80 to $4.57 range. That is -6% versus the projected 2031 average. That marks a +27% change versus current levels. Momentum favours further upside here.
By 2033, ATOS could reach as high as $5.28, with a base case around $3.12 and support toward $1.98 — roughly +44% from $2.17. Buyers look set to stay in control over this stretch.
Expect ATOS to range from $2.40 to $6.69 through 2034. The $3.87 average target implies a +78% move from current prices. That is up +24% on the projected 2033 average. Momentum favours further upside here.
The ATOS price prediction for 2035 points to an average of $4.03 (low $2.45, high $7.10) — a potential gain of +86% on today's $2.17. Buyers look set to stay in control over this stretch.
In 2040, ATOS is projected to trade between $2.56 and $8.98, averaging $4.71 — a potential gain of +117% from today's $2.17. That is up +17% on the projected 2035 average. Momentum favours further upside here.
Atossa Therapeutics, Inc.'s 2050 outlook centres on $7.93, within a $3.57 to $16.90 range. That is up +68% on the projected 2040 average. That marks a +266% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in ATOS today (≈ 460.829493 ATOS) could be worth
$3,655.91
+$2,655.91 (+266%) by 2050 · US Dollar
Based on the average projected ATOS price of $7.93 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ATOSwould be worth at today's price.
$1,000 invested in ATOS on Jul 31, 2025 (≈ 80.321286 ATOS) would be worth
$174.3
-$825.7 (-82.6%) today · 0.17× · US Dollar
Based on a ATOS entry price of $12.45 vs. today's $2.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.3 | $943.48 | -5.7% |
| 1 month ago | $2.04 | $1,063.73 | +6.4% |
| 3 months ago | $5.33 | $407.13 | -59.3% |
| 6 months ago | $5.59 | $388.19 | -61.2% |
| 1 year ago | $12.45 | $174.3 | -82.6% |
| All time (5.0y) ago | $49.95 | $43.44 | -95.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ATOS forecast.
Our base-case forecast reaches $4.30 around 2040.
Implied market cap at $4.30: $42.89M
The multi-year forecast shows a bullish path from 2027 onward, with an avg price rising from $2.62 (2027) to $7.57 (2050). The forecast lists a 2027 avg of $2.62 with a 26.5% ROI, 2040 avg of $4.51 with a 117.7% ROI, and 2050 avg of $7.57 with a 265.7% ROI.
Max price projections rise to $16.12 by 2050, underscoring substantial upside potential if the upper bounds materialize. The sentiment attached to the longer-horizon years is BULLISH, while 2026 is NEUTRAL with an avg of $2.07 and 0% ROI.
These figures are estimates and not guarantees; they reflect projected ranges and market expectations rather than certainties.
Tap a question to reveal the answer.
2030: avg $2.62, min $1.81, max $4.13, ROI 26.8%, sentiment BULLISH.
Forecasts show a bullish trajectory from 2027 onward, with avg price rising to $7.57 and max $16.12 by 2050 and ROI up to 265.7%. These are estimates, not guarantees.
The max in 2050 is $16.12, which includes potential for reaching $10; however, these are estimates and not guarantees.
Neutral sentiment with RSI14 at 30; SMA50 $3.01; SMA200 $6.95; support $1.75; resistance $2.49; 30-day range $1.61-$2.67; volatility 70%.
Current price is $2.07 with a market cap of $20.65M; the stock ranks 4854.
Atossa Therapeutics, Inc. Community Discussion
0Share your Atossa Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.